Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer

This publication has 32 references indexed in Scilit:

• Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women.
  Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994
• Tamoxifen: How Boldly to Go Where No Women Have Gone Before
  JNCI Journal of the National Cancer Institute, 1993
• Cardiac and Thromboembolic Morbidity Among Postmenopausal Women With Early Stage Breast Cancer in a Randomized Trial of Adjuvant Tamoxifen
  JNCI Journal of the National Cancer Institute, 1993
• Increased concentrations of serum lipoprotein (a) in response to growth hormone treatment.
  BMJ, 1993
• Lipoprotein (a)
  Current Opinion in Lipidology, 1993
• A Risk-Benefit Assessment of Tamoxifen Therapy
  Drug Safety, 1993
• Long term effects of tamoxifen on blood lipid values in breast cancer.
  BMJ, 1992
• Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid
  Atherosclerosis, 1992
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
  The Lancet, 1992
• Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanozolol
  Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1984